Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: A single-center cohort study

International Urology and Nephrology

Volumn 46, Issue 1, 2014, Pages 151-159

  Ogawa, Tetsuya ^a   Shimizu, Himiko ^b   Kyono, Ai ^a   Sato, Masayo ^b   Yamashita, Tetsuri ^a   Otsuka, Kuniaki ^a   Nitta, Kosaku ^b  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Epoetin dose; Hemodialysis; Hemoglobin level; Mortality; Renal anemia

Indexed keywords

AGED; ANEMIA; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893837539     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-013-0494-z     Document Type: Article

References (25)

1. Eschbach JW, Egrie JC, Downing MR et al (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78 (Pubitemid 17052741)
2. Macdougall IC, Cooper A (2002) The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 17(Suppl 1):48-52 (Pubitemid 34157120)
3. Zhang Y, Thamer M, Stefanik K et al (2004) Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44:866-876 (Pubitemid 39445919)
4. Kilpatrick R, Critchlow C, Fishbane S et al (2008) Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3:1077-1083
5. Locatelli F, Pisoni R, Combe C, Bommer J, Andreucci VE, Piera L, Greenwood R, Feldman HI, Port FK, Held PJ et al (2004) Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:121-132 (Pubitemid 38072623)
6. Robinson BM, Joffe MM, Berns JS et al (2005) Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68:2323-2330 (Pubitemid 43117811)
7. Szczech LA, Barnhart HX, Inrig JK et al (2008) Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74:791-798
8. Johnson DW, Pollock CA, Macdougall IC (2007) Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 12:321-330 (Pubitemid 47075419)
9. Kalantar-Zadeh K, Lee GH, Miller JE et al (2009) Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 53:823-834
10. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease (2006) Am J Kidney Dis 47 (5 Suppl 3): S16-S145
11. Locatelli F, Aljama P, Bárány P (2004) European best practice guidelines working group: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (Suppl 2): ii1-ii47
12. Akizawa T, Pisoni RL, Akiba T (2008) Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS. Nephrol Dail Transplant 23:3643-3653
13. Chung S, Song HC, Shin SJ et al (2012) Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int 16:181-187
14. Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4:1205-1213
15. Gejyo F, Saito A, Akizawa T et al (2004) Japanese society for dialysis therapy. Ther Apher Dial 8:443-459
16. Regidor D, Kopple J, Kovesdy C (2006) Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17:1181-1191
17. Szczech LA, Barnhart HX, Sapp S et al (2010) A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int 77:239-246
18. Fukuma S, Yamaguchi T, Hashimoto S et al (2012) Erythropoiesis- stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 59:108-116
19. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al (2003) Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42:761-773 (Pubitemid 37187377)
20. Stenvinkel P (2001) The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16(Suppl 7):36-40 (Pubitemid 33062121)
21. Smrzova Jm Balla J, Barany P (2005) Inflammation and resistance to erythropoiesis-stimulating agents-What do we know and what needs to be clarified? Nephrol Dial Transplant 20 (Suppl 8): viii2-viii7
22. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K, Soma M et al (2011) Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes. Int J Artif Organs 34:16-25
23. Kaysen GA, Muller HG, Ding J, Chertow GM (2006) Challenging the validity of the EPO index. Am J Kidney Dis 47:157-166 (Pubitemid 41828278)
24. Nakai S, Iseki K, Itami N et al (2012) An overview of regular dialysis treatment in Japan (as of 31 December 2010). Ther Apher Dial 16:483-521
25. Hasegawa T, Bragg-Gresham JL, Pisoni RL et al (2011) Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Kidney Int 79:340-346